Comparison of Prognostic Genomic Predictors in Colorectal Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Apr 30

PMID 23626670

Citations 11

Authors

Yun-Yong Park

Sung Sook Lee

Jae Yun Lim

Sang Cheol Kim

Sang Bae Kim

Bo Hwa Sohn

In-Sun Chu

Sang Cheul Oh

Eun Sung Park

Woojin Jeong

Sung Soo Kim

Scott Kopetz

Ju-Seog Lee

Affiliations

Soon will be listed here.

Abstract

Background: Although several prognostic genomic predictors have been identified from independent studies, it remains unclear whether these predictors are actually concordant with respect to their predictions for individual patients and which predictor performs best. We compared five prognostic genomic predictors, the V7RHS, the ColoGuideEx, the Meta163, the OncoDX, and the MDA114, in terms of predicting disease-free survival in two independent cohorts of patients with colorectal cancer.

Study Design: Using original classification algorithms, we tested the predictions of five genomic predictors for disease-free survival in two cohorts of patients with colorectal cancer (n = 229 and n = 168) and evaluated concordance of predictors in predicting outcomes for individual patients.

Results: We found that only two predictors, OncoDX and MDA114, demonstrated robust performance in identifying patients with poor prognosis in 2 independent cohorts. These two predictors also had modest but significant concordance of predicted outcome (r>0.3, P<0.001 in both cohorts).

Conclusions: Further validation of developed genomic predictors is necessary. Despite the limited number of genes shared by OncoDX and MDA114, individual-patient outcomes predicted by these two predictors were significantly concordant.

Citing Articles

Enhancing chemotherapy response prediction via matched colorectal tumor-organoid gene expression analysis and network-based biomarker selection.

Zhang W, Wu C, Huang H, Bleu P, Zambare W, Alvarez J Transl Oncol. 2025; 52():102238.

PMID: 39754813 PMC: 11754497. DOI: 10.1016/j.tranon.2024.102238.

Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer.

Xu C, Xia P, Li J, Lewis K, Ciombor K, Wang L Cell Rep Med. 2024; 5(8):101661.

PMID: 39059386 PMC: 11384724. DOI: 10.1016/j.xcrm.2024.101661.

Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.

Koncina E, Haan S, Rauh S, Letellier E Cancers (Basel). 2020; 12(2).

PMID: 32019056 PMC: 7072488. DOI: 10.3390/cancers12020319.

Cancer stem cell associated eight gene-based signature predicts clinical outcomes of colorectal cancer.

Dong C, Cui D, Liu G, Xu H, Peng X, Duan J Oncol Lett. 2019; 17(1):442-449.

PMID: 30655785 PMC: 6313194. DOI: 10.3892/ol.2018.9533.

Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.

Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N Clin Cancer Res. 2018; 24(16):3867-3877.

PMID: 29514841 PMC: 6095767. DOI: 10.1158/1078-0432.CCR-17-3236.

References

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Eschrich S, Yang I, Bloom G, Kwong K, Boulware D, Cantor A . Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005; 23(15):3526-35. DOI: 10.1200/JCO.2005.00.695. View

Garman K, Acharya C, Edelman E, Grade M, Gaedcke J, Sud S . Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A. 2011; 108(42):17569. PMC: 3198325. DOI: 10.1073/pnas.1115170108. View

Puppa G, Sonzogni A, Colombari R, Pelosi G . TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med. 2010; 134(6):837-52. DOI: 10.5858/134.6.837. View

Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C . Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2010; 29(1):17-24. DOI: 10.1200/JCO.2010.30.1077. View

Gray R, Quirke P, Handley K, Lopatin M, Magill L, Baehner F . Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011; 29(35):4611-9. DOI: 10.1200/JCO.2010.32.8732. View

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

Laurie J, MOERTEL C, Fleming T, Wieand H, Leigh J, Rubin J . Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989; 7(10):1447-56. DOI: 10.1200/JCO.1989.7.10.1447. View

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Tangen C . Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995; 122(5):321-6. DOI: 10.7326/0003-4819-122-5-199503010-00001. View

10.

Kopetz S, Abbruzzese J . Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clin Cancer Res. 2009; 15(24):7451-7452. DOI: 10.1158/1078-0432.CCR-09-2523. View

11.

Simon R, Lam A, Li M, Ngan M, Menenzes S, Zhao Y . Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2009; 3:11-7. PMC: 2675854. View

12.

Laibe S, Lagarde A, Ferrari A, Monges G, Birnbaum D, Olschwang S . A seven-gene signature aggregates a subgroup of stage II colon cancers with stage III. OMICS. 2012; 16(10):560-5. DOI: 10.1089/omi.2012.0039. View

13.

Garman K, Acharya C, Edelman E, Grade M, Gaedcke J, Sud S . A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A. 2008; 105(49):19432-7. PMC: 2592987. DOI: 10.1073/pnas.0806674105. View

14.

Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C . Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene. 2004; 23(7):1377-91. DOI: 10.1038/sj.onc.1207262. View

15.

Jiang Y, Casey G, Lavery I, Zhang Y, Talantov D, Martin-McGreevy M . Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn. 2008; 10(4):346-54. PMC: 2438204. DOI: 10.2353/jmoldx.2008.080011. View

16.

Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

17.

Oh S, Park Y, Park E, Lim J, Kim S, Kim S . Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut. 2011; 61(9):1291-8. PMC: 3419333. DOI: 10.1136/gutjnl-2011-300812. View

18.

Barrier A, Boelle P, Roser F, Gregg J, Tse C, Brault D . Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol. 2006; 24(29):4685-91. DOI: 10.1200/JCO.2005.05.0229. View

19.

Jorissen R, Gibbs P, Christie M, Prakash S, Lipton L, Desai J . Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res. 2009; 15(24):7642-7651. PMC: 2920750. DOI: 10.1158/1078-0432.CCR-09-1431. View

20.

Clark-Langone K, Sangli C, Krishnakumar J, Watson D . Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer. 2010; 10:691. PMC: 3016296. DOI: 10.1186/1471-2407-10-691. View